Literature DB >> 17339673

The global market for ADHD medications.

Richard M Scheffler1, Stephen P Hinshaw, Sepideh Modrek, Peter Levine.   

Abstract

Little is known about the global use and cost of medications for attention deficit hyperactivity disorder (ADHD). Global use of ADHD medications rose threefold from 1993 through 2003, whereas global spending (2.4 billion US dollars in 2003) rose ninefold, adjusting for inflation. Per capita gross domestic product (GDP) robustly predicted use across countries, but the United States, Canada, and Australia showed significantly higher-than-predicted use. Use and spending grew in both developed and developing countries, but spending growth was concentrated in developed countries, which adopted more costly, long-acting formulations. Promoting optimal prescription and monitoring should be a priority.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339673     DOI: 10.1377/hlthaff.26.2.450

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  47 in total

1.  Prescription psychostimulant abuse.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2007-09

2.  Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

Authors:  Catherine A Fullerton; Arnold M Epstein; Richard G Frank; Sharon-Lise T Normand; Christina X Fu; Thomas G McGuire
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

3.  Stimulant ADHD medication and risk for substance abuse.

Authors:  Zheng Chang; Paul Lichtenstein; Linda Halldner; Brian D'Onofrio; Eva Serlachius; Seena Fazel; Niklas Långström; Henrik Larsson
Journal:  J Child Psychol Psychiatry       Date:  2013-10-25       Impact factor: 8.982

Review 4.  Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Authors:  Benedetto Vitiello
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

Review 5.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

Review 6.  Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.

Authors:  Ilina Singh; Angela M Filipe; Imre Bard; Meredith Bergey; Lauren Baker
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

7.  Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.

Authors:  Britahny M Baskin; Bríd Á Nic Dhonnchadha; Linda P Dwoskin; Kathleen M Kantak
Journal:  Psychopharmacology (Berl)       Date:  2017-07-20       Impact factor: 4.530

8.  The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.

Authors:  Alexander Viktorin; Eleonore Rydén; Michael E Thase; Zheng Chang; Cecilia Lundholm; Brian M D'Onofrio; Catarina Almqvist; Patrik K E Magnusson; Paul Lichtenstein; Henrik Larsson; Mikael Landén
Journal:  Am J Psychiatry       Date:  2016-10-03       Impact factor: 18.112

9.  Acute dose-related differential effects of methylphenidate on murine cystometric parameters.

Authors:  Sung Ho Choi; Young Sam Cho; Sung Tae Cho; Tack Lee; Khae Hawn Kim
Journal:  Int Neurourol J       Date:  2013-12-31       Impact factor: 2.835

10.  Forecasting drug utilization and expenditure in a metropolitan health region.

Authors:  Björn Wettermark; Marie E Persson; Nils Wilking; Mats Kalin; Seher Korkmaz; Paul Hjemdahl; Brian Godman; Max Petzold; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-05-17       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.